Connect Biopharma Holdings Limited (CNTB)
NGM – Real Time Price. Currency in USD
0.76
-0.04 (-4.51%)
At close: Oct 22, 2026, 4:00 PM EDT
0.76
-0.00 (-0.28%)
Pre-market: Oct 23, 2026, 8:03 AM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
0.76
-0.04 (-4.51%)
At close: Oct 22, 2026, 4:00 PM EDT
0.76
-0.00 (-0.28%)
Pre-market: Oct 23, 2026, 8:03 AM EDT
No Data
There are no news for this stock.
Company's cash reserves $27.0M significantly exceed its total debt $596.0K, ensuring strong financial flexibility
Total current assets $38.6M exceed Total current liabilities $16.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.1), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$16.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.37 | 4.66 | 10 | |
| Quick ratio | 2.37 | 4.27 | 10 | |
| Debt to Equity | 0.02 | 0.15 | 9.0 | |
| Debt to Assets | 0.01 | 0.11 | 9.0 | |
| Interest coverage | N/A | -3.18 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 26M | 64K | 3M |
| Gross Profit | -1M | -720K | 25M | N/A | -176K |
| Operating Income | -118M | -69M | -22M | -58M | -70M |
| Net Income | -118M | -62M | -16M | -55M | -69M |
| EBITDA | -117M | -68M | -22M | -57M | -70M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | 83.18 | 1.0 | |
| Operating margin % | -635.98 | -29.82 | 1.0 | |
| Net margin % | -624.42 | -41.34 | 1.0 | |
| EBITDA margin % | -630.17 | -26.03 | 1.0 | |
| Cash flow margin % | -584.80 | -43.91 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| ROA | -70.51 | -20.69 | 1.0 | |
| ROE | -82.72 | -17.54 | 1.0 | |
| ROIC | -82.47 | -18.98 | 1.0 | |
| ROCE | -167.07 | -25.49 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 15.89 | 5.0 |
| Next quarter | N/A | 39.1 | 5.5 |
| Current year | 11842.47 | -2.13 | 5.5 |
| Next year | 99.14 | 24.13 | 10 |
| Weighted average score | 6.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 1537.87 | 10.9 | 19.94 | -1.13 | 6.8 |
| Y/Y | 5666.67 | -33.98 | -16.38 | -24.87 | 3.3 |
| 3y average | 632.75 | -44.2 | -43.67 | -2.76 | 3.3 |
| 5y average | 779.25 | -34.09 | -16.65 | -54.18 | 3.3 |
| Weighted average score | 4.2 | ||||
| NAME | RATIO | INDUSTRY | 5Q TREND | SCORE |
|---|---|---|---|---|
| P/E | N/A | 20.20 | 1.0 | |
| PEG (5yr expected) | N/A | 1.20 | 1.0 | |
| P/S | 17.00 | 10.07 | 3.2 | |
| P/B | 1.87 | 4.38 | 7.6 | |
| Weighted average score | 3.2 | |||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | N/A | 1.20 | N/A |
| Payout ratio | N/A | 27.45 | N/A |
| 5-year dividend growth rate | N/A | 4.94 | N/A |
| Years of dividend increase | 0.00 | 0.00 | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | N/A | N/A |
| Intangible assets | N/A | N/A |
| Switching costs | N/A | N/A |
| Network effect | N/A | N/A |
| Economies of scale | N/A | N/A |
| Weighted average score | 1.0 | |